Arthrocare Device Use Draws More Scrutiny
News of the restatement sent the stock reeling; shares were recently up 3.6% to $27.35.
By then, SIG Susquehanna analyst David Turkaly had already downgraded Arthrocare twice and adopted a negative view of the company's stock even though his firm still owned the shares. Turkaly, for one, has worried about DiscoCare from the start.
"As questions arose regarding the acquisition, management responded to investor concerns by stating that there was nothing unusual going on within the DiscoCare unit, and these were traditional business practices that were very common in the industry," Turkaly wrote last month, following news of the planned restatement. But "if DiscoCare's business practices were in fact very common in the industry, we are left to wonder: Why was the accounting of this relationship and subsequent transaction so difficult to get right?
"Here we are yet again, with more controversy surrounding the now-infamous DiscoCare."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV